333742-48-6
333742-48-6
Chemical Structure
AZD8309
- CAS No.: 333742-48-6
- Formula:C15H14F2N4O2S2
- Molecular Weight:384.42
IUPAC Name: (R)-5-((2,3-difluorobenzyl)thio)-7-((1-hydroxypropan-2-yl)amino)thiazolo[4,5-d]pyrimidin-2(3H)-one
InChIKey: SRHSMXLXWORYJK-SSDOTTSWSA-N
SMILES: O=C1SC2=C(N=C(N=C2N1)SCC3=CC=CC(F)=C3F)N[C@@H](CO)C
Biological Activity: AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZD8309 | 99.98% | AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NVP CXCR2 20 | NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZ10397767 | AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC50 of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRT3190 | 99.84% | SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rugocrixan | 99.54% | AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CXCR2 antagonist 4 | CXCR2 antagonist 4 (compound 7) is a potent CXCR2 antagonist with an IC50 value of 0.13 μM. CXCR2 antagonist 4 can inhibit CXCL8-induced cytosolic calcium increase (IC50 = 27 μM). CXCR2 antagonist 4 can be used for researching anticancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CXCR2 antagonist 5 | CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC50=0.013 µM) and calcium mobilization (IC50=0.1 µM)[ 1]. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CCR7 antagonist 1 | 99.55% | CCR7 antagonist 1 (30c) is a dual CXCR2 (IC50 of 11.02 μM) and CCR7 (IC50 of 0.43 μM) antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRT3109 | 99.68% | SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fosrugocrixan | Fosrugocrixan is an antagonist for CX3C chemokine receptor 1 (CX3CR1) that exhibits anti-inflammatory activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZD-5069 | 99.91% | AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
